Cambium Bio (ASX:CMB) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 04, 2026)


ASX:CMB Cambium Bio Ltd ASX:CMB
35 GF Score
Price A$0.44
! 4 Warning Signs
View Full Analysis

What is Cambium Bio 5-Year Yield-on-Cost %?

Cambium Bio ASX:CMB -1.14% 35 5-Year Yield-on-Cost % is 0.00 as of Jul. 04, 2026. GuruFocus rates ASX:CMB with a GF Score™ of 35/100. The stock has 4 warning signs investors should review. Among 153 Biotechnology companies, Cambium Bio ranks worse than 653594.12% on this metric.

Cambium Bio's yield on cost for the quarter that ended in Dec. 2025 was 0.00.


The historical rank and industry rank for Cambium Bio's 5-Year Yield-on-Cost % or its related term are showing as below:



ASX:CMB's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.72
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Cambium Bio  (ASX:CMB) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Cambium Bio 5-Year Yield-on-Cost % Related Terms


ASX:CMB vs VRTX, REGN, ALNY: 5-Year Yield-on-Cost % Comparison

For the Biotechnology subindustry, Cambium Bio's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cambium Bio 5-Year Yield-on-Cost % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cambium Bio's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Cambium Bio's 5-Year Yield-on-Cost % falls into.


ASX:CMB
35GF Score
Cambium Bio Ltd ASX:CMB
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cambium Bio 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Cambium Bio is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Cambium Bio (ASX:CMB) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 04, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Cambium Bio and its competitors. According to the industry distribution chart, Cambium Bio ranks #999999 out of 153 companies in the Biotechnology industry.
Is Cambium Bio's 5-Year Yield-on-Cost % too high?
Cambium Bio's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Cambium Bio ranks #999999 out of 153 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cambium Bio has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Cambium Bio's 5-Year Yield-on-Cost % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cambium Bio ranks #999999 out of 153 companies for 5-Year Yield-on-Cost %. This places Cambium Bio in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.72. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.72, based on 153 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Cambium Bio and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cambium Bio's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambium Bio stock overvalued right now?
Cambium Bio (ASX:CMB) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. Cambium Bio's overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Cambium Bio (ASX:CMB), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cambium Bio Business Description

Address Unit 2.06, 31 Lexington Drive, Bella Vista, NSW, AUS, 2153
Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate, Elate Ocular, is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.
35GF Score

Get the complete analysis for ASX:CMB

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.44
Price